KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics
Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of... KayoThera selected as a finalist in TechUnited’s Propelify Event
Kayothera was selected as one of four finalists in this year’s Propelify event, a premier event celebrating technology and innovation in the tri-state area. Kayothera will be pitching at the BetterWellness challenge at 1:10 pm on October 6. The judges will award... BIO Announces KayoThera as the 2021 Start-up Stadium Winner
The Biotechnology Innovation Organization (BIO) today announced that Kayothera Inc. is the winner of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 16 finalists were evaluated by expert judges with... Kayothera selected as finalist in BIO’s Start-up Stadium
Kayothera will be presenting on their novel immune oncology pipeline during the week of June 10 at BIO’s annual meeting. Pitches for the Startup Stadium will go live on Thursday followed by voting.